Analyse EyePoint, Inc. (EYPT) — Kairos Score 53/100

À propos de EyePoint, Inc.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

3 transactions — 1 achats et 0 ventes déclarés par les dirigeants de EyePoint, Inc..

🏦 Hedge Funds

17 fonds institutionnels déclarent une position sur EYPT dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur EYPT.

• EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.